Connect with us


AstraZeneca Increases Its Commitment to Spain with More Investments

AstraZeneca’s commitment to the Spanish territory can also be seen in the creation of infrastructure since it has allocated a total of €5.5 million for the construction of new offices, as well as the formation of the innovation hub in Madrid. The company is part of the Partnership for Health System Sustainability and Resilience (Phssr).



AstraZeneca plans to increase its investments in Spain. In 2021, the British company invested more than €93 million in Spain, dedicated to innovative projects, and €48 million of that figure were reserved to carry out innovation and development (R&D) projects.

The investment made in 2022 was close to €400 million. Over the past year, the Cambridge-based pharmaceutical company increased its workforce in Spain by 20%, reaching 1,300 employees and planning to hire around a thousand more people in the coming years.

The Government of Spain welcomes the company’s commitment since “it will allow the creation of quality jobs and is in line with the announcements of multimillion-dollar investments from multinationals in all sectors in recent months, and reflects the determined drive that It is being given to the fields of R&D, health, and science with the investments of the Recovery Plan”, the First Vice President of the Government, Nadia Calviño, announced.

If you want to read more about AstraZeneca and the investments the British pharmaceutical company is planning in Spain, download for free our companion app. The Born2Invest mobile app brings you the most important financial news of the day so you can stay informed.

In 2022, AstraZeneca carried out around 300 clinical trials in Spain

The pharmaceutical company conducts clinical trials in different areas, including oncology, cardiovascular diseases, vaccines, and immunotherapy, as well as rare and respiratory diseases. AstraZeneca currently has 179 clinical development programs and of these fifteen are entirely new molecular entities. In the last year, the company carried out, in Spain, nearly 300 clinical trials in which more than 4,500 patients collaborated.

Pascal Soriot, CEO of AstraZeneca has pointed out that “the Spanish R&D ecosystem is first class and we are committed to working with the Spanish Government to unleash the potential of innovative medicines as an engine of long-term economic growth.” He also said that “we will continue to invest and increase our capacities in environments committed to innovation and development.”

The company’s commitment to the Spanish territory can also be seen in the creation of infrastructure since it has allocated a total of €5.5 million for the construction of new offices, as well as the formation of the innovation hub in Madrid.

The company is part of the Partnership for Health System Sustainability and Resilience (Phssr), which has entered into an agreement with the Vall d’Hebron Institute of Oncology (Vhio) to promote preclinical and translational research with other academics, groups, and companies.


(Featured image by akirEVarga via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.